Efficacy and safety of sodium-glucose co-transporter (SGLT2) inhibitor in diabetic patients with chronic liver disease
Not Applicable
Recruiting
- Conditions
- Diabetic patients with chronic liver disease
- Registration Number
- JPRN-UMIN000035015
- Lead Sponsor
- Kitasato University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Type 1 diabetes 2. Patients with severe ketosis or diabetic coma 3. Patients with diabetes insidious 4 Patients with Estimated Glomerular Filtration Rate (eGFR) of 45 mL / min / 1.73 m ^ 2 or less 5. Patients with malignancy 6. Patients with end-stage liver failure who have hepatic ascites, child-Pugh class BC and hepatic encephalopathy 7. Pregnant women or patients with potential pregnancy 8. Patients who research managers judged inappropriate as subjects
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method